Amyris Making Headway In Fermentation-Derived Cannabinoids; CBD Could Hit Market In Early 2020
Synthetic biology firm Amyris has shipped to partner Lavvan its first cannabinoid produced via genetically engineered yeast. While Amyris’ announcement does not identify the specific cannabinoid, Lavvan leadership indicated in March 2019 that fermentation-derived CBD would be first to market, representing potential purity and value benefits compared with CBD extracted from the cannabis plant.
You may also be interested in...
Amyris plans to launch new Rose Inc. cosmetics in the third quarter of 2021. “We believe cosmetics to be the next opportunity for us to transform to clean,” says Amyris CEO John Melo. News in brief.
Cosmetics Market In 2019: CBD, Microplastic And US Sunscreen Uncertainty Among Year’s Biggest Issues
The opportunity represented by cannabidiol, and the uncertain future for commonly used sunscreen active ingredients in the US and microplastic in the EU, were issues of high interest among cosmetics industry stakeholders in 2019.
CBD Suits Challenge ‘THC-Free’ Claims After Users Fail Drug Tests; Plaintiffs Bar May Just Be Warming Up
Attorneys are warning CBD product marketers to be on guard for litigation challenging the authenticity of their claims, the safety of their products and other aspects of their businesses. So far, suits of this nature have been limited in the US, but the few known cases could be harbingers of a larger wave to come.